{
  "id": "RL33782",
  "type": "CRS Report",
  "typeId": "REPORTS",
  "number": "RL33782",
  "active": false,
  "source": "EveryCRSReport.com, University of North Texas Libraries Government Documents Department",
  "versions": [
    {
      "source": "EveryCRSReport.com",
      "id": 344566,
      "date": "2007-04-19",
      "retrieved": "2016-04-07T18:10:55.986029",
      "title": "Federal Drug Price Negotiation: Implications for Medicare Part D",
      "summary": "The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) established a prescription drug benefit for Medicare beneficiaries under Part D, which began on January 1, 2006. One provision of MMA, the \u201cnoninterference\u201d clause, expressly forbids the Secretary of Health and Human Services (HHS) from interfering with drug price negotiation between manufacturers and Medicare drug plan sponsors, and from instituting a formulary or price structure for prescription drugs. The framework created by the law emphasizes competition among the Medicare drug plans to obtain price discounts.\nApproaches that the federal government could adopt to affect prescription drug prices range from dictating an outcome, such as imposing statutory mandates or establishing price ceilings, to more market-oriented approaches such as soliciting competitive bids from voluntary participants. A reference pricing approach combines elements of both. Some of these methods are currently employed by the Department of Veterans Affairs (VA) and the Medicaid program. The price the VA pays for a drug is the lowest price as determined through one of four methods, less an additional 5% prime vendor discount: (1) the federal ceiling price, (2) federal supply schedule, (3) performance-based incentive agreement, or (4) national standardization contract. Drug reimbursement costs under Medicaid are calculated differently for single-source (only one Food and Drug Administration-approved product) and multiple-source drugs (more than one FDA-approved product). However, for both types of drugs, state reimbursements are determined in aggregate based on either the federal upper limit price (FUL)\u2014a predetermined percentage of a defined reference price\u2014or the estimated acquisition cost. Drug manufacturers also enter into agreements with the Secretary of HHS and provide rebates to the states that reflect the lowest price that manufacturers offer to other purchasers of their drugs.\nThere are many practical and legislative steps necessary before federal drug price negotiation for Medicare beneficiaries could take place. Repealing the noninterference clause is a necessary first step, but may not be sufficient to lead to federally negotiated prices. If the Secretary were to engage in activities that affect drug prices on behalf of Medicare Part D beneficiaries, there might be consequences that affect the price of drugs for Medicare beneficiaries as well as other public and private patients, the number and types of drugs that would be available to Part D beneficiaries, the amount of research and development and innovation by pharmaceutical companies, and other sectors of the industry. Both H.R. 4 and S. 3 would strike the noninterference provision in MMA while maintaining the prohibition against price setting and the establishment of a formulary, but H.R. 4 would also require the Secretary of HHS to negotiate prescription drug prices. Because the absence of a formulary would limit the Secretary\u2019s bargaining leverage, CBO has scored each bill as having \u201ca negligible effect on federal spending.\u201d On January 12, 2007, the House passed H.R. 4, the Medicare Prescription Drug Price Negotiation Act of 2007, and on April 18, 2007, the Senate did not invoke cloture on S. 3, the Medicare Fair Prescription Drug Price Act of 2007. This report will be updated.",
      "type": "CRS Report",
      "typeId": "REPORTS",
      "active": false,
      "formats": [
        {
          "format": "HTML",
          "encoding": "utf-8",
          "url": "http://www.crs.gov/Reports/RL33782",
          "sha1": "b3dc400350d1615cc54a8c9caeff75ffe71373b3",
          "filename": "files/20070419_RL33782_b3dc400350d1615cc54a8c9caeff75ffe71373b3.html",
          "images": null
        },
        {
          "format": "PDF",
          "encoding": null,
          "url": "http://www.crs.gov/Reports/pdf/RL33782",
          "sha1": "9905c17d86701b4fabd31d51ebf203dd01747476",
          "filename": "files/20070419_RL33782_9905c17d86701b4fabd31d51ebf203dd01747476.pdf",
          "images": null
        }
      ],
      "topics": []
    },
    {
      "source": "University of North Texas Libraries Government Documents Department",
      "sourceLink": "https://digital.library.unt.edu/ark:/67531/metadc818415/",
      "id": "RL33782_2007Jan05",
      "date": "2007-01-05",
      "retrieved": "2016-03-19T13:57:26",
      "title": "Federal Drug Price Negotiation: Implications for Medicare Part D",
      "summary": null,
      "type": "CRS Report",
      "typeId": "REPORT",
      "active": false,
      "formats": [
        {
          "format": "PDF",
          "filename": "files/20070105_RL33782_04da5b6cd5ebc0165d12911e17818710e7dbcdbe.pdf"
        },
        {
          "format": "HTML",
          "filename": "files/20070105_RL33782_04da5b6cd5ebc0165d12911e17818710e7dbcdbe.html"
        }
      ],
      "topics": []
    }
  ],
  "topics": [
    "Health Policy"
  ]
}